Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 5Hodgkin Disease 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Oligodendroglioma 1Neoplasms 1Melanoma Neoplasms 1Lymphoma 1Lung Neoplasms 1Leiomyosarcoma 1Kidney Neoplasms 1Hematologic Diseases 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × Dacarbazine × Clear all
NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡